TWC
CLRB icon

TD Waterhouse Canada’s Cellectar Biosciences CLRB Stock Holding History

TD Waterhouse Canada’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$154 Hold
63
– – ﹤0.01% 2201
2025
Q4 		$181 Buy
+63
New +$233 ﹤0.01% 1944

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

TD Waterhouse Canada's CLRB Position: Q1 2026 in Review

TD Waterhouse Canada held its Cellectar Biosciences (CLRB) position steady in Q1 2026 at 63 shares worth $154. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

TD Waterhouse Canada first reported a position in CLRB in Q4 2025 and has held it in 2 quarters since. The position peaked at $181 in Q4 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q1 2026.

  • TD Waterhouse Canada held 63 shares of Cellectar Biosciences worth $154 as of Q1 2026.
  • TD Waterhouse Canada left its Cellectar Biosciences share count unchanged in Q1 2026.
  • Cellectar Biosciences made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q1 2026, its #2201 holding.
  • TD Waterhouse Canada first reported a position in Cellectar Biosciences in Q4 2025 and has held it in 2 quarters since.
  • TD Waterhouse Canada's Cellectar Biosciences position peaked at $181 in Q4 2025.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.